Top Trader: Why I'm Sticking With Sarepta

Shares of Sarepta Pharmaceutical sinking today after the FDA rejected the company's experimental drug to treat Muscular Dystrophy. Despite the drop, "Halftime Report" expert Jon Najarian is bullish on the stock long-term.

Najarian sees the sell-off as a buying opportunity calling it "the gift that keeps on giving...I thought last week's selloff was overdone and bought the name at $11.40." He believes it can enhance the yield in your portfolio dramatically.

He may be bullish but he does note that the stock isn't for everyone: "the wild ride is not for everybody and certainly not for your retirement account."

Jon is long Sarepta and Sarepta calls.